AR034320A1 - Forma de dosificacion farmaceutica del mesilato de nelfinavir amorfo - Google Patents

Forma de dosificacion farmaceutica del mesilato de nelfinavir amorfo

Info

Publication number
AR034320A1
AR034320A1 ARP020101580A ARP020101580A AR034320A1 AR 034320 A1 AR034320 A1 AR 034320A1 AR P020101580 A ARP020101580 A AR P020101580A AR P020101580 A ARP020101580 A AR P020101580A AR 034320 A1 AR034320 A1 AR 034320A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical dosage
dosage form
amorfo
mesilate
nelfinavir
Prior art date
Application number
ARP020101580A
Other languages
English (en)
Inventor
Martin Howard Infeld
Navnit Hargovindas Shah
Lin Zhang
Wantanee Phuapradit
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR034320A1 publication Critical patent/AR034320A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una forma de dosificación farmacéutica oral unitaria sólida de mesilato de nelfinavir amorfo que comprende mesilato de nelfinavir amorfo, y un polímero sintético, no iónico, de bloqueo de óxido de etileno y óxido de propileno, soluble en agua, farmacéuticamente aceptable, teniendo dicho copolímero un punto de fusión de al menos 40°C. Se proporciona un proceso de granulación de fusión caliente para la elaboración de una forma de dosificación. Forma de dosificación oral unitaria sólida para uso en terapia, particularmente para el tratamiento de enfermedades mediadas por HIV.
ARP020101580A 2001-05-03 2002-04-30 Forma de dosificacion farmaceutica del mesilato de nelfinavir amorfo AR034320A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28841001P 2001-05-03 2001-05-03

Publications (1)

Publication Number Publication Date
AR034320A1 true AR034320A1 (es) 2004-02-18

Family

ID=23106974

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101580A AR034320A1 (es) 2001-05-03 2002-04-30 Forma de dosificacion farmaceutica del mesilato de nelfinavir amorfo

Country Status (36)

Country Link
US (1) US7014866B2 (es)
EP (1) EP1390063B1 (es)
JP (1) JP4101661B2 (es)
KR (1) KR100554816B1 (es)
CN (1) CN1255185C (es)
AR (1) AR034320A1 (es)
AT (1) ATE282428T1 (es)
BG (1) BG108311A (es)
BR (1) BR0209325A (es)
CA (1) CA2444116C (es)
CZ (1) CZ20033211A3 (es)
DE (1) DE60201988T2 (es)
EA (1) EA006627B1 (es)
EC (1) ECSP034827A (es)
ES (1) ES2231717T3 (es)
GE (1) GEP20053466B (es)
GT (1) GT200200079A (es)
HR (1) HRP20030873B1 (es)
HU (1) HU229938B1 (es)
IL (2) IL158306A0 (es)
IS (1) IS7010A (es)
JO (1) JO2401B1 (es)
MA (1) MA27018A1 (es)
MX (1) MXPA03009971A (es)
MY (1) MY128509A (es)
NO (1) NO20034689L (es)
NZ (1) NZ528689A (es)
PA (1) PA8544501A1 (es)
PE (1) PE20021159A1 (es)
PL (1) PL366998A1 (es)
PT (1) PT1390063E (es)
RS (1) RS83503A (es)
SK (1) SK14572003A3 (es)
TW (1) TWI234461B (es)
UA (1) UA76463C2 (es)
WO (1) WO2002089835A2 (es)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2398226A1 (en) * 2002-01-28 2003-07-28 Pfizer Inc. Increased-dosage nelfinavir tablet and method of making same
EP1652525A4 (en) * 2003-07-15 2008-10-01 Arigen Inc ANTI-VIRUS CORONA DRUG
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP1701704A2 (en) * 2003-12-31 2006-09-20 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
RU2382648C2 (ru) * 2004-12-03 2010-02-27 Мерк Энд Ко., Инк. Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
ATE453384T1 (de) 2005-09-23 2010-01-15 Hoffmann La Roche Neue dosierformulierung
CN101330906B (zh) * 2005-12-14 2010-12-29 弗·哈夫曼-拉罗切有限公司 Hcv前药制剂
EP1962808B1 (en) * 2005-12-14 2010-09-29 F. Hoffmann-La Roche AG Hcv prodrug formulation
UY30535A1 (es) * 2006-08-10 2008-03-31 Cipla Ltd Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.
WO2008021347A2 (en) * 2006-08-16 2008-02-21 Novartis Ag Method for making solid dispersions of highly crystalline therapeutic compounds
WO2008067164A2 (en) * 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
CA2681628C (en) 2007-03-16 2016-10-18 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
US7528131B2 (en) * 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
ES2401914T3 (es) 2007-04-25 2013-04-25 Concert Pharmaceuticals Inc. Análogos de Cilostazol
US9194512B2 (en) 2007-04-30 2015-11-24 Mark Andreychuk Coiled tubing with heat resistant conduit
CA2630084A1 (en) * 2007-04-30 2008-10-30 Mark Andreychuk Coiled tubing with retainer for conduit
MX370608B (es) * 2007-05-01 2019-12-18 Concert Pharmaceuticals Inc Compuestos de morfinano.
CA2685924A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl)acetamides
EP3632916B1 (en) 2007-05-01 2022-06-08 Concert Pharmaceuticals Inc. Morphinan compounds
DK2792662T3 (da) 2007-05-01 2016-07-25 Concert Pharmaceuticals Inc Morphinanforbindelser
MX2009013565A (es) 2007-06-12 2010-06-02 Concert Pharmaceuticals Inc Derivados de azapeptidos.
EP2212298B1 (en) * 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
WO2009052391A1 (en) * 2007-10-19 2009-04-23 Purdue Research Foundation Solid formulations of crystalline compounds
ITMI20080227A1 (it) * 2008-02-13 2009-08-14 Felice Vinati '' dispositivo di sicurezza per apparati di sollevamento a fune ''
KR20100121527A (ko) 2008-02-29 2010-11-17 콘서트 파마슈티컬즈, 인크. 치환된 잔틴 유도체
US20110160253A1 (en) * 2008-05-28 2011-06-30 Harbeson Scott L Deuterated tizanidine
WO2010019557A1 (en) * 2008-08-12 2010-02-18 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
JP5730769B2 (ja) 2008-09-19 2015-06-10 コンサート ファーマシューティカルズ インコーポレイテッド モルヒナン化合物
US20120083487A1 (en) 2008-10-30 2012-04-05 Amanda Thomas Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurolgical diseases, intractable and chronic pain and brain injury
WO2010062690A1 (en) 2008-10-30 2010-06-03 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
EP2362779A4 (en) 2008-11-04 2013-03-20 Anchor Therapeutics Inc CXCR4 RECEPTOR COMPOUNDS
US20110313004A1 (en) 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2010107791A2 (en) 2009-03-17 2010-09-23 Concert Pharmaceuticals, Inc. Pyrazinoisoquinoline compounds
WO2010138889A1 (en) 2009-05-28 2010-12-02 Concert Pharmaceuticals, Inc. Peptides for the treatment of hcv infections
EP2454259A1 (en) 2009-06-23 2012-05-23 Concert Pharmaceuticals Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
WO2011103457A1 (en) 2010-02-18 2011-08-25 Concert Pharmaceuticals Inc. Pyrimidine derivatives
US9155795B2 (en) 2010-02-26 2015-10-13 Anchor Therapeutics, Inc. CXCR4 receptor compounds
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
EP3144296A1 (en) 2010-03-02 2017-03-22 Concert Pharmaceuticals, Inc. Deuterated tetrahydronaphthalene derivatives
US8900605B2 (en) * 2010-06-14 2014-12-02 Ratiopharm Gmbh Solid ivabradine-containing composition
EP2616467A1 (en) 2010-09-13 2013-07-24 Concert Pharmaceuticals Inc. Substituted azaindoles
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
EP2678337A1 (en) 2011-02-25 2014-01-01 Concert Pharmaceuticals Inc. 2-amino-naphthyridine derivatives
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US20140128469A1 (en) 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
ME03652B (me) 2011-05-18 2020-07-20 Vertex Pharmaceuticals Europe Ltd Deuterisani derivati ivakaftora
US20140296263A1 (en) 2011-07-19 2014-10-02 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
FR2985177B1 (fr) * 2012-01-02 2016-04-01 Oreal Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs
CN104254540A (zh) 2012-01-09 2014-12-31 安科治疗公司 Apj受体化合物
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
CN104364255A (zh) 2012-04-13 2015-02-18 康塞特医药品有限公司 取代的黄嘌呤衍生物
EP2838879A1 (en) 2012-04-20 2015-02-25 Concert Pharmaceuticals Inc. Deuterated rigosertib
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
CA2908929C (en) 2012-07-12 2021-01-26 Concert Pharmaceuticals, Inc. Deuterated idebenone
BR112015003153A2 (pt) 2012-08-17 2017-07-04 Concert Pharmaceuticals Inc baricitinib deuterado
WO2014078842A1 (en) 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
AU2013361320A1 (en) 2012-12-20 2015-07-02 Concert Pharmaceuticals, Inc. Deuterated ALK inhibitors
US9789126B2 (en) 2012-12-21 2017-10-17 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
JP2016512831A (ja) 2013-03-15 2016-05-09 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたパルボシクリブ
WO2014150043A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
WO2015010045A1 (en) 2013-07-18 2015-01-22 Anchor Therapeutics, Inc. Apj receptor compounds
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
WO2015120393A1 (en) 2014-02-10 2015-08-13 Concert Pharmaceuticals, Inc. Substituted triazolobenzodiazepines
WO2015160913A1 (en) 2014-04-18 2015-10-22 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
WO2015188073A1 (en) 2014-06-06 2015-12-10 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
WO2016022955A1 (en) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
WO2016094011A1 (en) * 2014-12-11 2016-06-16 Merck Sharp & Dohme Corp. Crystal forms of a ccr5 antagonist
CN105769809A (zh) * 2014-12-23 2016-07-20 上海星泰医药科技有限公司 提高生物利用度的雷尼司他及其制备方法
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
EP3265440A1 (en) 2015-03-06 2018-01-10 Concert Pharmaceuticals Inc. Deuterated emricasan
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
US20180243289A1 (en) 2015-07-30 2018-08-30 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for treating agitation
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
HK1258472A1 (zh) 2015-09-21 2019-11-15 Vertex Pharmaceuticals (Europe) Limited 氘代cftr增效剂的施用
EP3377179B1 (en) 2015-11-19 2021-04-07 Concert Pharmaceuticals Inc. Deuterated epi-743
AU2016366310C1 (en) 2015-12-09 2021-09-09 Research Triangle Institute Improved apelin receptor (APJ) agonists and uses thereof
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
EP3825307B1 (en) 2016-07-04 2022-08-03 Avanir Pharmaceuticals, Inc. Methods for the synthesis of deuterated dextromethorphan
WO2018026833A1 (en) 2016-08-01 2018-02-08 The Brigham And Women's Hospital, Inc. Particles for delivery of proteins and peptides
EP3558996A4 (en) 2016-12-21 2020-08-05 Research Triangle Institute, International DIARYLPURINE DERIVATIVES WITH ENHANCED BIOAVAILABILITY
WO2018160717A1 (en) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
BR112019024177A2 (pt) 2017-05-19 2020-06-02 Superb Wisdom Limited Derivados de resiquimode
CA3082834A1 (en) 2017-11-22 2019-05-31 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
MX2021012409A (es) 2019-04-10 2021-11-12 Mayo Found Medical Education & Res Metodos y materiales para el tratamiento dependiente del genero de la disfuncion cardiovascular.
KR20220054391A (ko) 2019-08-29 2022-05-02 리서치 트라이앵글 인스티튜트 아펠린 수용체 작용제에 대한 방법 및 용도
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
CA3184471A1 (en) 2020-05-27 2021-12-02 The Penn State Research Foundation Antibacterial compounds
US20230390292A1 (en) 2020-10-28 2023-12-07 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
JP2024507574A (ja) 2021-02-25 2024-02-20 リサーチ トライアングル インスティテュート アペリン受容体アゴニストとしてのヘテロアリール誘導体
WO2023018904A1 (en) 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
AU2022328282A1 (en) 2021-08-12 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
WO2023215520A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6001851A (en) 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
ATE302597T1 (de) * 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
AU8145198A (en) * 1997-06-16 1999-01-04 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
EP1028712B1 (en) * 1997-09-19 2005-01-12 Shire Laboratories Inc. Solid solution beadlet
WO2001034118A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Solid dispersion pharmaceutical formulations
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation

Also Published As

Publication number Publication date
NO20034689D0 (no) 2003-10-20
PT1390063E (pt) 2005-03-31
EP1390063B1 (en) 2004-11-17
CN1255185C (zh) 2006-05-10
TWI234461B (en) 2005-06-21
DE60201988D1 (de) 2004-12-23
HK1070285A1 (en) 2005-06-17
UA76463C2 (en) 2006-08-15
IL158306A0 (en) 2004-05-12
PA8544501A1 (es) 2002-11-18
JP4101661B2 (ja) 2008-06-18
PL366998A1 (en) 2005-02-07
JP2004527569A (ja) 2004-09-09
US7014866B2 (en) 2006-03-21
PE20021159A1 (es) 2002-12-20
HUP0401238A2 (hu) 2004-12-28
NO20034689L (no) 2003-10-20
GT200200079A (es) 2002-12-05
ECSP034827A (es) 2003-12-24
HRP20030873A2 (en) 2005-08-31
IL158306A (en) 2008-11-03
JO2401B1 (en) 2007-06-17
DE60201988T2 (de) 2005-12-15
BG108311A (bg) 2004-12-30
HRP20030873B1 (en) 2006-04-30
EA200301166A1 (ru) 2004-04-29
ATE282428T1 (de) 2004-12-15
KR20040007523A (ko) 2004-01-24
EA006627B1 (ru) 2006-02-24
CZ20033211A3 (cs) 2004-09-15
HU229938B1 (en) 2015-01-28
WO2002089835A3 (en) 2003-05-01
EP1390063A2 (en) 2004-02-25
BR0209325A (pt) 2004-07-20
HUP0401238A3 (en) 2012-09-28
ES2231717T3 (es) 2005-05-16
RS83503A (sr) 2006-10-27
NZ528689A (en) 2005-03-24
CA2444116A1 (en) 2002-11-14
KR100554816B1 (ko) 2006-02-22
CN1547484A (zh) 2004-11-17
MXPA03009971A (es) 2004-02-12
SK14572003A3 (sk) 2004-12-01
MY128509A (en) 2007-02-28
GEP20053466B (en) 2005-02-25
CA2444116C (en) 2009-01-20
IS7010A (is) 2003-10-30
US20030021840A1 (en) 2003-01-30
WO2002089835A2 (en) 2002-11-14
MA27018A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
ECSP034827A (es) Forma de dosificacion farmaceutica de mesilato de nelfinavir amorfo
EP1120109A3 (en) Rapidly disintegrating and fast dissolving solid dosage form
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
DE602004009552D1 (de) Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel
WO2002024203A3 (en) Controlled release formulations for oral administration
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
NZ514558A (en) Viral treatment
PY0117547A (es) Composicion de eletriptan en forma de particulas.
SE9902935D0 (sv) Pharmaceutical compositions
CO5251412A1 (es) Composicion farmaceutica de mirtazapina para administracion peroral con cubierta polimerica
UY27278A1 (es) Forma de dosificación farmacéutica del mesilato de nelfinavir amorfo
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
ECSP003685A (es) Formulaciones orales de liberacion controlada
DK1152763T3 (da) Anvendelse af desozypeganin til behandling af stofafhængighed
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
EP1698338A3 (en) S-methyl-dihydro-ziprasidone for the treatment of schizophrenia
DE69830176D1 (de) Arzneimittel gegen infertilität, die mit endometriose assoziiert ist
PT1499278E (pt) Forma de dosagem farmaceutica de libertacao imediata compreendendo tibolona polimorfa
AR020998A1 (es) Formulaciones de liberacion controlada de metamizol
PE20020324A1 (es) Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina
EE200300096A (et) Arginiini ja selle farmatseutiliselt vastuvõetavate soolade kasutamine, antineoplastilist toimeainet ja arginiini sisaldava intravenoosselt manustatava preparaadi kasutamine, toode või komplekt kasutamiseks vähiravis ja preparaat intravenoosseks manu
AR018825A1 (es) Antagonistas del receptor de bradiquinina no peptidica para uso en el tratamiento de trastornos y enfermedades oftalmicas
NO20043841L (no) 1-fenyl-2-heteroaryl-substituerte benzimidazolderivater, anvendelsen derav for fremstilling av legemidler benyttet i behandlingen av immunologiske sykdommer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal